vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Nebius Group N.V. (NBIS). Click either name above to swap in a different company.
Nebius Group N.V. is the larger business by last-quarter revenue ($32.1M vs $18.7M, roughly 1.7× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-586.8M).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Nebius Group N.V., headquartered in Amsterdam, is a technology company that provides artificial intelligence infrastructure. The company also owns Avride and TripleTen, as well as stakes in Toloka and Clickhouse. It is headquartered in Amsterdam with offices in Israel and the United States.
CTMX vs NBIS — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $32.1M |
| Net Profit | $-154.0K | — |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -251.1% |
| Net Margin | -0.8% | — |
| Revenue YoY | -25.7% | — |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $32.1M | ||
| Q2 25 | $18.7M | $24.2M | ||
| Q1 25 | $50.9M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $79.6M | ||
| Q2 24 | $25.1M | $36.3M | ||
| Q1 24 | $41.5M | — | ||
| Q4 23 | $26.6M | — |
| Q3 25 | — | — | ||
| Q2 25 | $-154.0K | $-185.4M | ||
| Q1 25 | $23.5M | — | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-258.2M | ||
| Q2 24 | $-6.5M | $-118.3M | ||
| Q1 24 | $13.8M | — | ||
| Q4 23 | $837.0K | — |
| Q3 25 | — | -251.1% | ||
| Q2 25 | -6.9% | -754.1% | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | -366.1% | ||
| Q2 24 | -33.7% | -563.1% | ||
| Q1 24 | 28.1% | — | ||
| Q4 23 | -2.3% | — |
| Q3 25 | — | — | ||
| Q2 25 | -0.8% | -766.1% | ||
| Q1 25 | 46.2% | — | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -324.4% | ||
| Q2 24 | -26.0% | -325.9% | ||
| Q1 24 | 33.3% | — | ||
| Q4 23 | 3.1% | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $4.8B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $4.8B |
| Total Assets | $175.1M | $10.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $4.8B | ||
| Q2 25 | $49.0M | $1.7B | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | $2.3B | ||
| Q2 24 | $43.2M | $2.3B | ||
| Q1 24 | $36.2M | — | ||
| Q4 23 | $17.2M | — |
| Q3 25 | — | $4.8B | ||
| Q2 25 | $119.9M | $3.8B | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $2.9B | ||
| Q2 24 | $-31.2M | $4.3B | ||
| Q1 24 | $-31.7M | — | ||
| Q4 23 | $-47.4M | — |
| Q3 25 | — | $10.1B | ||
| Q2 25 | $175.1M | $5.1B | ||
| Q1 25 | $98.5M | — | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $3.0B | ||
| Q2 24 | $159.2M | $4.4B | ||
| Q1 24 | $184.7M | — | ||
| Q4 23 | $201.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-196.8M |
| Free Cash FlowOCF − Capex | $-15.8M | $-586.8M |
| FCF MarginFCF / Revenue | -84.6% | -1828.0% |
| Capex IntensityCapex / Revenue | 0.1% | 1215.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-196.8M | ||
| Q2 25 | $-15.8M | $-162.0M | ||
| Q1 25 | $-21.0M | — | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-26.0M | — | ||
| Q4 23 | $-22.0M | — |
| Q3 25 | — | $-586.8M | ||
| Q2 25 | $-15.8M | $-379.9M | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — | ||
| Q4 23 | $-22.2M | — |
| Q3 25 | — | -1828.0% | ||
| Q2 25 | -84.6% | -1569.8% | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — | ||
| Q4 23 | -83.5% | — |
| Q3 25 | — | 1215.0% | ||
| Q2 25 | 0.1% | 900.4% | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 1.0% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — | ||
| Q4 23 | -26.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NBIS
| Nebius | $27.1M | 84% |
| TripleTen | $6.3M | 20% |
| Avride | $100.0K | 0% |
